Inhaled amikacin versus placebo to prevent ventilator-associated pneumonia: the AMIKINHAL double-blind multicentre randomised controlled trial protocol
暂无分享,去创建一个
Q. Lu | F. Barbier | H. Merdji | F. Meziani | J. Helms | J. Quenot | S. Lasocki | T. Boulain | J. Lacherade | P. Lanotte | B. Veber | C. Dahyot-fizelier | D. Schnell | D. Roux | P. Andreu | R. Respaud | P. Seguin | N. Grégoire | S. Ehrmann | L. Vecellio | M. Ferrandiere | María Cabrera | E. Tavernier | G. Plantefeve | M. Nay | A. Veinstein | G. Beduneau | Jean-Etienne Herbrecht | G. Muller | D. Le Pennec | M. Landais | M. Leclerc | Mai-Anh Nay
[1] M. Klompas,et al. Ventilator-associated pneumonia in adults: a narrative review , 2020, Intensive Care Medicine.
[2] I. Cavero-Redondo,et al. Subglottic secretion drainage for preventing ventilator-associated pneumonia: an overview of systematic reviews and an updated meta-analysis , 2020, European Respiratory Review.
[3] R. Wunderink,et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. , 2019, The Lancet. Infectious diseases.
[4] C. Brun-Buisson,et al. Selective decontamination of the digestive tract (SDD) in critically ill patients: a narrative review , 2019, Intensive Care Medicine.
[5] H. Sax,et al. The preventable proportion of healthcare-associated infections 2005–2016: Systematic review and meta-analysis , 2018, Infection Control & Hospital Epidemiology.
[6] A. Kwa,et al. Importance of control groups when delineating antibiotic use as a risk factor for carbapenem resistance, extreme-drug resistance, and pan-drug resistance in Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review and meta-analysis. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[7] B. Pinheiro,et al. Effect of antibiotics administered via the respiratory tract in the prevention of ventilator‐associated pneumonia: A systematic review and meta‐analysis , 2018, Journal of critical care.
[8] J. Rello,et al. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study , 2016, European Journal of Clinical Microbiology & Infectious Diseases.
[9] J. Reitsma,et al. Selective digestive and oropharyngeal decontamination in medical and surgical ICU patients: individual patient data meta-analysis. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[10] R. Wunderink,et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia , 2017, European Respiratory Journal.
[11] P. Diot,et al. Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care , 2017, Annals of Intensive Care.
[12] M. Kollef,et al. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram‐Negative Ventilator‐Associated Pneumonia: IASIS Trial , 2017, Chest.
[13] T. Boulain,et al. Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients. , 2016, The Journal of antimicrobial chemotherapy.
[14] Peggy Cruse,et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] M. Balaan,et al. Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.
[16] Matthieu Jacobs,et al. Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients , 2014, Antimicrobial Agents and Chemotherapy.
[17] S. Nseir,et al. Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia , 2014, Critical Care.
[18] G. Smaldone,et al. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. , 2014, American journal of respiratory and critical care medicine.
[19] Rolf H H Groenwold,et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. , 2013, The Lancet. Infectious diseases.
[20] J. Reignier,et al. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial. , 2013, JAMA.
[21] M. Falagas,et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[22] M. Niederman,et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia , 2012, Intensive Care Medicine.
[23] Q. Lu,et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. , 2011, American journal of respiratory and critical care medicine.
[24] R. Knight,et al. UniFrac: an effective distance metric for microbial community comparison , 2011, The ISME Journal.
[25] J. A. Kaan,et al. Decontamination of the digestive tract and oropharynx in ICU patients. , 2009, The New England journal of medicine.
[26] J. I. Kennedy,et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia , 2009, Critical care.
[27] 古谷 良輔,et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.
[28] G. Paintaud,et al. Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects , 2008, Intensive Care Medicine.
[29] Martin Schumacher,et al. Sample sizes for clinical trials with time-to-event endpoints and competing risks. , 2005, Contemporary clinical trials.
[30] P. Bossuyt,et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial , 2003, The Lancet.
[31] C. Brun-Buisson,et al. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. , 2003, American journal of respiratory and critical care medicine.
[32] F. Saulnier,et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome , 2002, European Respiratory Journal.
[33] F. V. van Tiel,et al. Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study. , 2001, American journal of respiratory and critical care medicine.
[34] V L Yu,et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.
[35] D. Schoenfeld,et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.
[36] R. Koerner. Contribution of endotracheal tubes to the pathogenesis of ventilator-associated pneumonia. , 1997, The Journal of hospital infection.
[37] Notice , 1935, Journal of Symbolic Logic.
[38] D. Denning,et al. The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) EUCAST Technical Note on fluconazole. , 2009 .
[39] G. O’Toole,et al. Mechanisms of biofilm resistance to antimicrobial agents. , 2001, Trends in microbiology.
[40] G. Van den Berghe,et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. , 1997, Critical care medicine.
[41] P. Morgan. International committee of medical journal editors. , 1983, Canadian Medical Association journal.